96. クローン病 Crohn disease Clinical trials / Disease details


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

  
13 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-000609-38-GB
(EUCTR)
17/07/201710/05/2018A Phase 2B study of multiple doses to evaluate the safety and treatment benefits of MEDI2070 in subjects with Crohn's Disease who have failed or are Intolerant to Anti Tumor Necrosis Factor-Alpha TherapyA Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha-Therapy Crohn's Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Product Code: MEDI2070
INN or Proposed INN: Not assigned
Other descriptive name: Anti-IL-23 monoclonal antibody
Allergan LimitedNULLNot RecruitingFemale: yes
Male: yes
342Phase 2United States;Slovenia;Slovakia;Spain;Ukraine;Turkey;Russian Federation;Israel;Switzerland;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Belgium;Brazil;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
2EUCTR2015-000609-38-DE
(EUCTR)
10/05/201628/01/2016A Phase 2B study of multiple doses to evaluate the safety and treatment benefits of MEDI2070 in subjects with Crohn's Disease who have failed or are Intolerant to Anti Tumor Necrosis Factor-Alpha TherapyA Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha-Therapy Crohn's Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Product Code: MEDI2070
INN or Proposed INN: Not assigned
Other descriptive name: Anti-IL-23 monoclonal antibody
Allergan LimitedNULLNot RecruitingFemale: yes
Male: yes
342Phase 2United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Brazil;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
3EUCTR2015-000609-38-BE
(EUCTR)
21/04/201625/02/2016A Phase 2B study of multiple doses to evaluate the safety and treatment benefits of MEDI2070 in subjects with Crohn's Disease who have failed or are Intolerant to Anti Tumor Necrosis Factor-Alpha TherapyA Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha-Therapy Crohn's Disease
MedDRA version: 18.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Product Code: MEDI2070
INN or Proposed INN: Not assigned
Other descriptive name: Anti-IL-23 monoclonal antibody
MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UKNULLNot RecruitingFemale: yes
Male: yes
342Phase 2United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Brazil;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
4EUCTR2015-000609-38-HU
(EUCTR)
04/04/201624/02/2016A Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha-Therapy A Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha-Therapy Crohn's Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Product Code: MEDI2070
INN or Proposed INN: Not assigned
Other descriptive name: Anti-IL-23 monoclonal antibody
Allergan LimitedNULLNot RecruitingFemale: yes
Male: yes
342Phase 2United States;Slovenia;Slovakia;Spain;Ukraine;Turkey;Russian Federation;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Czech Republic;Canada;Poland;Belgium;Brazil;Australia;Bulgaria;Germany;Netherlands;Korea, Republic of
5EUCTR2015-000609-38-BG
(EUCTR)
30/03/201615/02/2016A Phase 2B study of multiple doses to evaluate the safety and treatment benefits of MEDI2070 in subjects with Crohn's Disease who have failed or are Intolerant to Anti Tumor Necrosis Factor-Alpha TherapyA Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha-Therapy Crohn's Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Product Code: MEDI2070
INN or Proposed INN: Not assigned
Other descriptive name: Anti-IL-23 monoclonal antibody
Allergan LimitedNULLNot RecruitingFemale: yes
Male: yes
342Phase 2United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Brazil;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
6EUCTR2015-000609-38-NL
(EUCTR)
24/03/201602/02/2016A Phase 2B study of multiple doses to evaluate the safety and treatment benefits of MEDI2070 in subjects with Crohn's Disease who have failed or are Intolerant to Anti Tumor Necrosis Factor-Alpha TherapyA Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha-Therapy - MEDI2070-LUX Crohn's Disease
MedDRA version: 18.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Product Code: MEDI2070
INN or Proposed INN: Not assigned
Other descriptive name: Anti-IL-23 monoclonal antibody
MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UKNULLNot RecruitingFemale: yes
Male: yes
342Phase 2United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Brazil;Australia;Bulgaria;Germany;Netherlands;Korea, Republic of
7EUCTR2015-000609-38-ES
(EUCTR)
29/02/201608/02/2016A Phase 2B study of multiple doses to evaluate the safety and treatment benefits of MEDI2070 in subjects with Crohn's Disease who have failed or are Intolerant to Anti Tumor Necrosis Factor-Alpha TherapyA Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn?s Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha-Therapy Crohn's Disease
MedDRA version: 18.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Product Code: MEDI2070
INN or Proposed INN: Not assigned
Other descriptive name: Anti-IL-23 monoclonal antibody
MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UKNULLNot RecruitingFemale: yes
Male: yes
342Phase 2United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Brazil;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
8EUCTR2015-000609-38-CZ
(EUCTR)
15/02/201629/01/2016A Phase 2B study of multiple doses to evaluate the safety and treatment benefits of MEDI2070 in subjects with Crohn's Disease who have failed or are Intolerant to Anti Tumor Necrosis Factor-Alpha TherapyA Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha-Therapy Crohn's Disease
MedDRA version: 18.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Product Code: MEDI2070
INN or Proposed INN: Not assigned
Other descriptive name: Anti-IL-23 monoclonal antibody
MedImmune LimitedNULLNot RecruitingFemale: yes
Male: yes
342Phase 2United States;Slovakia;Slovenia;Spain;Ukraine;Turkey;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Brazil;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of
9EUCTR2012-004098-26-DE
(EUCTR)
17/04/201303/01/2013Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy Crohn's Disease
MedDRA version: 19.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Other descriptive name: Anti-IL-23 monoclonal antibody
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
120Phase 2France;United States;Hungary;Czech Republic;Canada;Spain;Poland;Germany;Italy
10EUCTR2012-004098-26-FR
(EUCTR)
10/04/201325/09/2015Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy Crohn's Disease
MedDRA version: 18.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Other descriptive name: Anti-IL-23 monoclonal antibody
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
120Phase 2United States;France;Hungary;Czech Republic;Canada;Spain;Poland;Germany;Italy
11EUCTR2012-004098-26-HU
(EUCTR)
11/02/201311/01/2013Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy Crohn's Disease
MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Other descriptive name: Anti-IL-23 monoclonal antibody
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
120Phase 2France;United States;Czech Republic;Hungary;Canada;Spain;Poland;Germany;Italy
12EUCTR2012-004098-26-CZ
(EUCTR)
08/02/201307/01/2013Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy Crohn's Disease
MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
Other descriptive name: Anti-IL-23 monoclonal antibody
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
120Phase 2France;United States;Hungary;Czech Republic;Canada;Spain;Poland;Germany;Italy
13EUCTR2012-004098-26-ES
(EUCTR)
28/01/201322/01/2013Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn´s disease.A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn´s Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy Crohn´s Disease
MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MEDI2070
INN or Proposed INN: Not available
Other descriptive name: Anti-IL-23 monoclonal antibody
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
120Phase 2France;United States;Hungary;Czech Republic;Canada;Poland;Spain;Germany;Italy